Results 111 to 120 of about 134,700 (260)

Carrier‐free self‐assembled nanomedicine for combination‐therapy of acute myeloid leukemia

BMEMat, EarlyView.
CPDS combines drugs with three different mechanisms of action to achieve a multi‐mechanism combination therapy for AML by directly killing tumor cells and activating anti‐tumor immunity. Abstract As the main acute myeloid leukemia (AML) clinical treatment, the chemotherapy alone cannot meet the clinical therapeutic needs due to the high heterogeneity ...
Meihong Chai, Rui Zhang, Haiyin Yang, Jiyue Xing, Tianyuan Hu, Mengxi Zhu, Rui Li, Xiaoli Chen, Beibei Zhao, Yang Lan, Stefan Barth, Yuanyu Huang, Li Zhang, Mengjie Zhang, Huining He   +14 more
wiley   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, EarlyView.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source

Identification of T:B Cell Multimers After Bispecific T Cell Engagement, Using Both Conventional and Imaging Flow Cytometry

Cytometry Part A, EarlyView.
ABSTRACT Bispecific T cell engagers bring together T cells with malignant B cell targets to enable synapse formation and disease eradication of hematological malignancies. The proportion of T cells and their ability to bind to their targets varies between patients and may be a biomarker of response.
Joanne E. Davis, Mandy Ludford‐Menting, Helena Peng, Darryl N. Johnson, David S. Ritchie, Rachel Koldej   +5 more
wiley   +1 more source

Measurable residual disease by multicolor flow cytometry in acute myeloid leukemia: A comparison of peripheral blood and bone marrow

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Measurable residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) is well established in bone marrow (BM) samples for acute myeloid leukemia (AML), but its use in peripheral blood (PB) remains less developed. We adapted a semi‐automated and well validated MFC‐MRD assay, originally developed for BM, to PB aiming to evaluate ...
Jonas Schadt, Malte von Bonin, Uta Oelschlägel, Christoph Röllig, Christian Thiede, Leo Ruhnke, Martin Bornhäuser, Sebastian Brenner, Maximilian Alexander Röhnert   +8 more
wiley   +1 more source

Mature T‐cell leukemia/lymphoma with an NK‐like immunophenotype: A report of 7 cases

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Distinguishing T‐cell from NK‐cell neoplasms can occasionally be challenging, as neoplastic T cells can lose T‐cell markers such as surface CD3 (sCD3) and CD5 while acquiring NK‐cell markers such as CD16, CD56, and CD94. In this study, we present a series of 7 mature T‐cell lymphoma/leukemia cases with NK‐like immunophenotypes to clarify ...
Wei J. Wang, Sa A. Wang, Hong Fang, Jeffrey L. Jorgensen, Shimin Hu, Lianqun Qiu, Jie Xu, L. Jeffrey Medeiros, Wei Wang   +8 more
wiley   +1 more source

Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley   +1 more source

Severe Ulceronecrotic Evolution during Mogamulizumab Treatment in a Patient with Primary Cutaneous Peripheral T-cell Lymphoma. [PDF]

Acta Derm Venereol
Samaran Q, Duboëlle M, Marque A, Bres V, Dereure O.   +4 more
europepmc   +1 more source

Establishment of pediatric reference ranges for circulating naïve and memory T and B cell subsets guided by the human immunophenotyping consortium standardization initiative: A large, single center U.S. experience

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Our knowledge of the immune system continues to expand at a rapid pace, and this coupled with technological advances now enables us to interrogate both the breadth and the depth of the immune response at levels without precedent. This has also facilitated rapidly integrating some of this carefully vetted knowledge into clinical practice ...
Aaruni Khanolkar, Aisha Ahmed
wiley   +1 more source

Serum free fatty acid promotes tumor progression and predicts golidocitinib sensitivity in peripheral T-cell lymphoma. [PDF]

Blood Adv
Qin Y, Xia PH, Huang YH, Cheng S, Liu JY, Gao X, Cai MC, Wang C, Qiu YR, Hu S, Shi Q, Yang HX, Zhao JY, Wang L, Xiong J, Zhao WL.   +15 more
europepmc   +1 more source

DinoFlow: Self‐supervised pretraining in flow cytometry enables accurate detection of common hematopathological disorders

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Flow cytometry is an essential component of routine hematological lab testing. Many computational methods have been proposed for the analysis of flow cytometry data, but most have focused on supervised learning for just one or a few specific disorders.
Brendan O'Fallon, Muir Morrison, Mattia Medina Grespan, Nicholas C. Spies, David P. Ng   +4 more
wiley   +1 more source